FindTrial
Sign In

Application of targeted deep sequencing of circulating tumor DNA (ctDNA) in clinical evaluation of multiple myeloma

Application of targeted deep sequencing of circulating tumor DNA (ctDNA) in clinical evaluation of multiple myeloma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040795
Enrollment
Unknown
Registered
2020-12-10
Start date
2019-12-14
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Gold Standard:bone marrow NGS
Index test:circulating&#32
tumor&#32
DNA&#32
NGS

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Active multiple myeloma

Exclusion criteria

Exclusion criteria: (1) Plasma cell leukemia; (2) smoking myeloma (asymptomatic myeloma)

Design outcomes

Primary

MeasureTime frame
circulating DNA sequencing;—

Countries

China

Contacts

Public ContactLu Jin

Peking University People's Hospital

jin1lu@sina.com+86 13311491805

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026